AmerisourceBergen has entered a definitive agreement for the acquisition of PharmaLex from Auctus Capital Partners in a deal worth $1.29bn (€1.28bn) in cash, subject to specific adjustments.
The acquisition will expand the international solutions portfolio of AmerisourceBergen, aiding in advancing its position as a preferred partner for biopharmaceutical manufacturers.
This approach will support its manufacturer partners throughout the pharmaceutical development and marketing processes.
An international team of scientific, regulatory, and safety and compliance (GxP) specialists, PharmaLex is based in Germany.
The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product.
Additionally, it aids clients in introducing products to international markets and varied patient populations by delivering tech-driven services spanning from clinical development consultation to marketing authorisation.
On closing the deal, the results of PharmaLex will be included as a component within the International Healthcare Solutions sector of AmerisourceBergen.
The PharmaLex takeover will build upon the current European presence of AmerisourceBergen in pharmaceutical supply and biopharma manufacturer services expertise.
This latest development will progress various AmerisourceBergen’s strategic imperatives and boost its position to gain substantial growth prospects in the biopharma market.
Subject to necessary conditions and approvals, the acquisition is anticipated to conclude by March next year.
AmerisourceBergen chairman, president and CEO Steven Collis said: “AmerisourceBergen is committed to building on our leadership in speciality services through a continued focus on innovation and partnerships, and by acquiring PharmaLex, we will be able to further enhance our value proposition to pharmaceutical manufacturers, from emerging biotechs to global biopharmaceutical leaders.
“PharmaLex’s highly complementary business and strong market reputation will deepen our partnerships with manufacturers, advancing our role as a strategic partner of choice as we support end-to-end clinical and commercial enablement solutions for our pharma customers.”